ArticleIranian journal of basic medical sciences2018
The inhibitory effects of 20(R)-ginsenoside Rg3 on the proliferation, angiogenesis, and collagen synthesis of hypertrophic scar derived fibroblasts
Article in Iranian journal of basic medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Global trends and hotspots of natural medicines for pathological scar treatment: a visualized bibliometric analysis (2008-2025).Frontiers in medicine · 2026Pooled it
- Yin and Yang of ginsenosides: Molecular mechanisms of bidirectional regulation of angiogenesis.Journal of ginseng research · 2026Review
- Research Advances in Therapeutic Strategies and Drug Delivery Systems for Pathological Scars.Pharmaceutics · 2026Review
- [Aloe-emodin inhibits scar tissue fibrosis through thrombospondin-1-PI3k-Akt pathway].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2025Article
- Ginseng and ginseng byproducts for skincare and skin health.Journal of ginseng research · 2024Review
- Natural products for the treatment of hypertrophic scars: Preclinical and clinical studies.Heliyon · 2024Review
- Recent progress of electrospun nanofibers as burning dressings.RSC advances · 2024Review
- Polymer-Based Wound Dressings Loaded with Ginsenoside Rg3.Molecules (Basel, Switzerland) · 2023Review
- Renal function protection and the mechanism of ginsenosides: Current progress and future perspectives.Frontiers in pharmacology · 2023Review
- Ginsenoside Rb1 selectively improved keratinocyte functions in vitro without affecting tissue regeneration in zebrafish larvae tail regrowth.In vitro cellular & developmental biology. Animal · 2022Article
- Traditional Chinese medicine for hypertrophic scars-A review of the therapeutic methods and potential effects.Frontiers in pharmacology · 2022Review
- Article
- Anti-Angiogenic Properties of Ginsenoside Rg3.Molecules (Basel, Switzerland) · 2020Review
- Ginsenoside Rg3 protects mouse leydig cells against triptolide by downregulation of miR-26a.Drug design, development and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTherapeutic effect of many selectable methods applied in clinical practice for treating hypertrophic scar (HS) is not still so satisfactory. Meanwhile, a few medicines may lead to several undesirable complications. The traditional Chinese medicine, MATERIALS AND
methodsThe HS specimens were obtained from the patients aged from 15 to 36 years without systemic diseases and the primary cultured cells were isolated from the scar tissue and expanded
resultsThe outcomes demonstrated that
conclusionThis study provides sufficient
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.